Hcw biologics inc. received nasdaq staff determination letter

Company expected notice for continued deficiency and delist letter from the nasdaq stock market company intends to request hearing to appeal in a timely manner miramar, fla., dec. 23, 2024 (globe newswire) -- hcw biologics inc. (the “company” or “hcw biologics”) (nasdaq: hcwb), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported on december 17, 2024, the company received written notice from the listing qualifications staff (“staff”) that it had failed to re-gain compliance for continued listing requirements of the nasdaq global markets.
HCWB Ratings Summary
HCWB Quant Ranking